Abstract
Background. Studies have shown that
peroxisome proliferator-activated receptor-
Background. Studies have shown that
peroxisome proliferator-activated receptor-
M. Zeisberg, F. Strutz, and G. A. Müller, “Role of fibroblast activation in inducing interstitial fibrosis,” Journal of Nephrology, vol. 13, supplement 3, pp. S111–S120, 2000.
View at: Google ScholarY. Guan and M. D. Breyer, “Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease,” Kidney International, vol. 60, no. 1, pp. 14–30, 2001.
View at: Publisher Site | Google ScholarY. Guan, Y. Zhang, L. Davis, and M. D. Breyer, “Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans,” American Journal of Physiology, vol. 273, no. 6, pp. F1013–F1022, 1997.
View at: Google ScholarT. Yang, D. E. Michele, J. Park et al., “Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,” American Journal of Physiology, vol. 277, no. 6, pp. F966–F973, 1999.
View at: Google ScholarT. Ishizuka, O. Ito, L. Tan et al., “Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney,” Hypertension Research, vol. 26, no. 11, pp. 929–936, 2003.
View at: Publisher Site | Google ScholarS. Wakino, K. Hayashi, S. Tatematsu et al., “Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats,” Hypertension Research, vol. 28, no. 3, pp. 255–262, 2005.
View at: Publisher Site | Google ScholarA. B. Walker, E. K. Naderali, P. D. Chattington, R. E. Buckingham, and G. Williams, “Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro,” Diabetes, vol. 47, no. 5, pp. 810–814, 1998.
View at: Publisher Site | Google ScholarL.-J. Ma, C. Marcantoni, M. F. Linton, S. Fazio, and A. B. Fogo, “Peroxisome proliferator-activated receptor- agonist troglitazone protects against nondiabetic glomerulosclerosis in rats,” Kidney International, vol. 59, no. 5, pp. 1899–1910, 2001.
View at: Publisher Site | Google ScholarJ. Weissgarten, S. Berman, S. Efrati, M. Rapoport, Z. Averbukh, and L. Feldman, “Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats,” Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1198–1204, 2006.
View at: Publisher Site | Google ScholarU. Panchapakesan, S. Sumual, C. A. Pollock, and X. Chen, “PPAR- agonists exert antifibrotic effects in renal tubular cells exposed to high glucose,” American Journal of Physiology, vol. 289, no. 5, pp. F1153–F1158, 2005.
View at: Publisher Site | Google ScholarB. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda, “Peroxisome proliferator-activated receptor- ligands inhibit TGF-1-induced fibronectin expression in glomerular mesangial cells,” Diabetes, vol. 53, no. 1, pp. 200–208, 2004.
View at: Publisher Site | Google ScholarA. Maeda, S. Horikoshi, T. Gohda, T. Tsuge, K. Maeda, and Y. Tomino, “Pioglitazone attenuates TGF-1-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR),” Cell Biology International, vol. 29, no. 6, pp. 422–428, 2005.
View at: Publisher Site | Google ScholarA. Gumieniczek, “Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits,” Life Sciences, vol. 74, no. 5, pp. 553–562, 2003.
View at: Publisher Site | Google ScholarH. Kasuga, Y. Ito, S. Sakamoto et al., “Effects of anti-TGF- type II receptor antibody on experimental glomerulonephritis,” Kidney International, vol. 60, no. 5, pp. 1745–1755, 2001.
View at: Publisher Site | Google ScholarS.-L. Lin, R.-H. Chen, Y.-M. Chen et al., “Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor,” Journal of the American Society of Nephrology, vol. 16, no. 9, pp. 2702–2713, 2005.
View at: Publisher Site | Google ScholarF. Zheng, A. Fornoni, S. J. Elliot et al., “Upregulation of type I collagen by TGF- in mesangial cells is blocked by PPAR- activation,” American Journal of Physiology, vol. 282, no. 4, pp. 639–648, 2002.
View at: Google ScholarD.-H. Cho, Y. J. Choi, S. A. Jo, and I. Jo, “Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPAR gamma-independent signaling pathways,” Journal of Biological Chemistry, vol. 279, no. 4, pp. 2499–2506, 2004.
View at: Publisher Site | Google ScholarH. Sawano, M. Haneda, T. Sugimoto, K. Inoki, D. Koya, and R. Kikkawa, “15-deoxy--prostaglandin inhibits IL-1-induced cyclooxygenase-2 expression in mesangial cells,” Kidney International, vol. 61, no. 6, pp. 1957–1967, 2002.
View at: Publisher Site | Google ScholarS. Zafiriou, S. R. Stanners, T. S. Polhill, P. Poronnik, C. A. Pollock et al., “Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses,” Kidney International, vol. 65, no. 5, pp. 1647–1653, 2004.
View at: Publisher Site | Google ScholarF. J. Villarreal and J. Asbun, “Peroxisome proliferator-activated receptors ligands, oxidative stress, and cardiac fibroblast extracellular matrix turnover,” Hypertension, vol. 44, no. 5, pp. 621–622, 2004.
View at: Publisher Site | Google ScholarT. Asano, M. Wakisaka, M. Yoshinari et al., “Peroxisome proliferator-activated receptor 1 (PPAR1) expresses in rat mesangial cells and PPAR agonists modulate its differentiation,” Biochimica et Biophysica Acta, vol. 1497, no. 1, pp. 148–154, 2000.
View at: Publisher Site | Google ScholarY. Ping, H. Xiaohui, L. Yongxue, and Z. Yali, “Activation of peroxisome proliferator-activated receptor in human endothelial cells increases plasminogen activator inhibitor type-1 expression,” Chinese Medical Journal, vol. 116, no. 1, pp. 29–33, 2003.
View at: Google ScholarS. Zafiriou, S. R. Stanners, S. Saad, T. S. Polhill, P. Poronnik, and C. A. Pollock, “Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. 638–645, 2005.
View at: Publisher Site | Google ScholarU. Panzer, A. Schneider, Y. Guan et al., “Effects of different PPAR-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis,” Kidney International, vol. 62, no. 2, pp. 455–464, 2002.
View at: Publisher Site | Google ScholarY. Shi and J. Massagué, “Mechanisms of TGF- signaling from cell membrane to the nucleus,” Cell, vol. 113, no. 6, pp. 685–700, 2003.
View at: Publisher Site | Google ScholarA. Leask and D. J. Abraham, “TGF- signaling and the fibrotic response,” The FASEB Journal, vol. 18, no. 7, pp. 816–827, 2004.
View at: Publisher Site | Google ScholarK. C. Flanders, “Smad3 as a mediator of the fibrotic response,” International Journal of Experimental Pathology, vol. 85, no. 2, pp. 47–64, 2004.
View at: Publisher Site | Google ScholarW. Wang, V. Koka, and H. Y. Lan, “Transforming growth factor- and Smad signalling in kidney diseases,” Nephrology, vol. 10, no. 1, pp. 48–56, 2005.
View at: Publisher Site | Google ScholarJ. Yang, C. Dai, and Y. Liu, “Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction,” The American Journal of Pathology, vol. 163, no. 2, pp. 621–632, 2003.
View at: Google Scholar